Xylem Inc.

“Xylem is a good but not exceptional water infrastructure business operating in a non-discretionary, secular growth market — its moat is real and widening, driven by high switching costs, a 30M+ installed base, and Evoqua's managed services layer. However, ROIC is currently at or below WACC, the $6.1B goodwill load from the Evoqua acquisition creates a credible (if minority-probability) path to permanent capital impairment if integration synergies disappoint, and the stock is priced at full value with minimal margin of safety. The 10-year compounding case (~8-9% CAGR) is credible but execution-dependent. Track for a better entry point — sub-$100 would offer meaningful margin of safety — or for confirmed ROIC recovery evidence.”